Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 865-871

  Osako, Tomo ^a   Ito, Yoshinori ^a   Ushijima, Masaru ^b   Takahashi, Shunji ^a   Tokudome, Nahomi ^a   Sugihara, Tsutomu ^a   Iwase, Takuji ^a   Matsuura, Masaaki ^b,c   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

Capecitabine; Metastatic breast cancer; Overall survival; Predictive factors; Time to treatment failure

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA METASTASIS; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THORAX WALL CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; PLEURAL NEOPLASMS; PRODRUGS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE;

EID: 61449139171     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0806-7     Document Type: Article

References (34)

1. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori N Shimma I Umeda H Ishitsuka 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281
2. T Osako Y Ito S Takahashi N Tokudome T Iwase K Hatake 2007 Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer Tumori 93 129 132
3. P Fumoleau R Largillier C Clippe V Dièras H Orfeuvre T Lesimple S Culine B Audhuy D Serin H Curé E Vuillemin JF Morère F Montestruc Z Mouri M Namer 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542
4. EA Wist HH Sommer B Ostenstad T Risberg Y Bremnes I Mjaaland 2004 Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer Acta Oncol 43 186 189
5. G Liu E Franssen MI Fitch E Warner 1997 Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 110 115
6. MM Borner P Schoffski R de Wit F Caponigro G Comella A Sulkes G Greim GJ Peters K van der Born J Wanders RF de Boer C Martin P Fumoleau 2002 Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer Eur J Cancer 38 349 358
7. C Twelves S Gollins R Grieve L Samuel 2006 A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer Ann Oncol 17 239 245
8. C Twelves M Boyer M Findlay J Cassidy C Weitzel C Barker B Osterwalder C Jamieson K Hieke Xeloda Colorectal Cancer Study Group 2001 Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma Eur J Cancer 37 597 604
9. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
10. GN Hortobagyi TL Smith SS Legha KD Swenerton EA Gehan HY Yap AU Buzdar GR Blumenschein 1983 Multivariate analysis of prognostic factors in metastatic breast cancer J Clin Oncol 1 776 786
11. J Aisner C Cirrincione M Perloff M Perry D Budman J Abrams L Panasci H Muss M Citron J Holland 1995 Combination chemotherapy for metastatic or recurrent carcinoma of the breast-a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281 J Clin Oncol 13 1443 1452
12. JY Pierga P Fumoleau Y Brewer L Zelek D Martin FL Turpin MJ Goudier M Gil-Delgado JL Baticle M Namer P Chollet W Sutherland JC Barats Cooperative Group of the French capecitabine compassionate use program 2004 Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program Breast Cancer Res Treat 88 117 129
13. M Rabinovich C Vallejo A Bianco J Perez M Machiavelli B Leone A Romero R Rodriguez M Cuevas C Dansky 1992 Development and validation of prognostic models in metastatic breast cancer: a GOCS study Oncology 49 188 195
14. K Inoue M Ogawa N Horikoshi K Aiba T Mukaiyama N Mizunuma S Itami A Hirano A Matsuoka T Matsumura 1991 Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer Jpn J Clin Oncol 21 334 339
15. G Falkson R Gelman CI Falkson J Glick J Harris 1991 Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study J Clin Oncol 9 2153 2161
16. N Yamamoto T Watanabe N Katsumata Y Omuro M Ando H Fukuda Y Takue M Narabayashi I Adachi S Takashima 1998 Construction and validation of a practical prognostic index for patients with metastatic breast cancer J Clin Oncol 16 2401 2408
17. G Blanco K Holli M Heikkinen OP Kallioniemi P Taskinen 1990 Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading Br J Cancer 62 142 146
18. MF Fey KW Brunner RW Sonntag 1981 Prognostic factors in metastatic breast cancer Cancer Clin Trials 4 237 247
19. JW Zinser GN Hortobagyi AU Buzdar TL Smith G Fraschini 1987 Clinical course of breast cancer patients with liver metastases J Clin Oncol 5 773 782
20. G Pentheroudakis G Fountzilas D Bafaloukos V Koutsoukou D Pectasides D Skarlos E Samantas HP Kalofonos H Gogas N Pavlidis 2006 Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women Breast Cancer Res Treat 97 237 244
21. CA Bertelsen AE Giuliano DH Kern BD Mann DJ Roe DL Morton 1984 Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response J Surg Res 37 257 263
22. Y Maehara Y Emi Y Sakaguchi T Kusumoto Y Kakeji S Kohnoe K Sugimachi 1990 Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue Eur Surg Res 22 50 55
23. HD Bear S Anderson A Brown R Smith EP Mamounas B Fisher R Margolese H Theoret A Soran DL Wickerham N Wolmark 2003 National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165 4174
24. JC Allegra ME Lippman EB Thompson R Simon 1978 An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer Cancer Res 38 4299 4304
25. JF Stewart RJ King SA Sexton RR Millis RD Rubens JL Hayward 1981 Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer Eur J Cancer 17 449 453
26. A Howell DM Barnes RN Harland J Redford VH Bramwell MJ Wilkinson R Swindell D Crowther RA Sellwood 1984 Steroid-hormone receptors and survival after first relapse in breast cancer Lancet 1 588 591
27. RD Rubens RJ King S Sexton MJ Minton JL Hayward 1980 Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer Cancer Chemother Pharmacol 4 43 45
28. C Knuefermann Y Lu B Liu W Jin K Liang L Wu M Schmidt GB Mills J Mendelsohn Z Fan 2003 HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 22 3205 3212
29. MD Pegram RS Finn K Arzoo M Beryt RJ Pietras DJ Slamon 1997 The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 537 547
30. BA Gusterson RD Gelber A Goldhirsch KN Price J Säve-Söderborgh R Anbazhagan J Styles CM Rudenstam R Golouh R Reed 1992 Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1049 1056
31. S Paik J Bryant C Park B Fisher E Tan-Chiu D Hyams ER Fisher ME Lippman DL Wickerham N Wolmark 1998 erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1361 1370
32. T Osako Y Ito S Takahashi N Tokudome T Iwase K Hatake 2008 Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer Cancer Chemother Pharmacol 62 159 164
33. G Schaller I Fuchs T Gonsch J Weber A Kleine-Tebbe P Klare HJ Hindenburg V Lakner A Hinke N Bangemann 2007 Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes J Clin Oncol 25 3246 3250
34. D Yamamoto S Iwase K Kitamura H Odagiri C Yamamoto Y Nagumo 2008 A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial Cancer Chemother Pharmacol 61 509 514